Smoking Cessation Intervention for Severe Mental Ill Health Trial (SCIMITAR+) : study protocol for a randomised controlled trial by Peckham, Emily et al.
STUDY PROTOCOL Open Access
Smoking Cessation Intervention for Severe
Mental Ill Health Trial (SCIMITAR+): study
protocol for a randomised controlled trial
Emily Peckham1* , Catherine Arundel2, Della Bailey1, Stuart Brownings3, Caroline Fairhurst2, Paul Heron4,
Jinshuo Li1, Steve Parrott1 and Simon Gilbody1
Abstract
Background: Smoking is highly prevalent among people who have experience of severe mental ill health,
contributing to their poor physical health. Despite the ‘culture’ of smoking in mental health services, people with
severe mental ill health often express a desire to quit smoking; however, the services currently available to aid
quitting are those which are widely available to the general population and may not be suitable or effective for
people with severe mental ill health. The aim of this study is to explore the effectiveness and cost-effectiveness of a
bespoke smoking-cessation intervention specifically targeted at people with severe mental ill health.
Methods/design: SCIMITAR+ is a multicentre, pragmatic, two-arm, parallel-group, individually randomised
controlled trial.
We aim to recruit 400 participants aged 18 years and above with a documented diagnosis of bipolar disorder,
schizophrenia or schizoaffective disorder who smoke. Potentially eligible participants identified in primary or
secondary care will be screened, and baseline data collected. Eligible, consenting participants will be randomly
allocated to one of two groups. In the intervention arm, the participant will be assigned a mental health
professional trained to deliver smoking-cessation interventions who will work with the participant and participant’s
GP or mental health specialist to provide an individually tailored smoking-cessation service. The comparator arm
will be usual care – following current NICE guidelines for smoking cessation, in line with general guidance that is
offered to all smokers, with no specific adaptation or enhancement in relation to severe mental ill health.
The primary outcome will be self-reported smoking cessation at 12 months verified by expired carbon monoxide
(CO) measurement. Secondary outcome measures include Body Mass Index at 12 months, the Fagerström Test for
Nicotine Dependence, Motivation to Quit questionnaire, SF-12, PHQ-9, GAD-7, EQ-5D-5 L, and health service
utilisation at 6 and 12 months. The economic evaluation at 12 months will be conducted in the form of an
incremental cost-effectiveness analysis.
Discussion: SCIMITAR+ trial is the largest trial to our knowledge to investigate the effectiveness of a bespoke
smoking-cessation service for people with severe mental ill health.
Trial registration: International Standard Randomised Controlled Trials Number, ISRCTN72955454. Registered on 16
January 2015.
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Background
The physical health of people with severe mental ill
health (SMI), such as schizophrenia and bipolar disorder,
is often poor with people with a diagnosis of schizophre-
nia reported to die 20–25 years earlier than those in the
general population [1]. One of the largest contributory
factors to this early mortality is smoking [2]. Smoking is
a preventable health hazard, with proven associations
with diseases such as cancer and heart disease. A recent
study compared outcomes for people with SMI who
smoke to people with SMI who do not smoke and found
that on average people with SMI who smoke die nearly
10 years earlier than those who do not smoke [3]. Smok-
ing is, therefore, one of the most important modifiable
risk factors for this excess mortality, though smoking
may be only one of several reasons for this observed dif-
ference. However, whilst the number of people in the
general population who smoke has been steadily declin-
ing over recent decades [4], the number of people with
SMI who smoke has not been declining at the same rate.
People with SMI are still more likely to smoke [5] and
to smoke more heavily, extracting more nicotine from
each cigarette, than those in the general population [6].
Estimates of the percentage of people with SMI who
smoke vary depending on the setting with up to 70% of
inpatients smoking [7, 8]. Despite this, the percentage of
people with SMI who, when asked, express a desire to
cut down or quit smoking is not dissimilar to that in the
general population when asked the same question [9].
However, although people with SMI express a desire to
quit smoking they are less likely to receive help in quit-
ting compared with the general population [10, 11]. This
is in part due to the culture of smoking within mental
health services amongst staff and patients [12, 13] where
cigarettes in the past have been used as a currency
between service users. There are widely held myths
about the therapeutic function of smoking and that
smoking relieves anxiety when in fact nicotine can in-
crease anxiety [14]. In addition, smoking is perceived by
some to help alleviate depression whereas a systematic
review has found smoking cessation to reduce depres-
sion [15]. Furthermore, conventional NHS approaches to
smoking cessation do not take into account the add-
itional challenges that people with SMI may face when
attempting to quit smoking. Conventional services
place a strong emphasis on being able to set a quit date
from the outset which may deter people with SMI. In
addition, smoking-cessation services for people with
SMI are not yet sufficiently evolved or embedded
within the NHS.
In order to address these problems, we have developed
a bespoke smoking-cessation intervention specifically
tailored to people with SMI. We initially piloted this
intervention in the Smoking Cessation Intervention for
severe Mental Ill health Trial (SCIMITAR) to assess its
acceptability and uptake by people with SMI [16]. In our
bespoke smoking-cessation intervention, a mental health
nurse or allied health professional is trained to deliver
smoking-cessation interventions and to work with the
individual and their GP or Community Mental Health
Team (CMHT). They advise on antismoking medication
and provide behavioural support in the form of infor-
mation, encouragement, and motivational sessions on
cutting down to quitting, setting quit dates and main-
taining smoking abstinence. The service is similar to that
offered in regular smoking-cessation services, but with
specific adaptations of medication and tailored behav-
ioural support to the individual needs of people with
SMI. The SCIMITAR pilot trial found the intervention
to be acceptable to people with SMI and that it was feas-
ible to recruit and retain participants, randomising 97
participants to receive either the bespoke smoking-
cessation service or usual care [16]. The clinical and
cost-effectiveness of this bespoke smoking-cessation ser-
vice will now be evaluated in the definitive randomised
controlled SCIMITAR+ trial.
Research objectives
1. To establish the clinical effectiveness of a bespoke
smoking-cessation intervention compared with usual
care for people with severe mental ill health.
2. To establish the cost-effectiveness of a bespoke
smoking-cessation intervention for people with
severe mental ill health.
Methods/design
The SCIMITAR+ study is a two-arm, pragmatic, parallel-
group, randomised controlled trial. It is a multicentre
study (22 sites in the UK) recruiting from both specialist
mental health services and primary care and aims to
recruit a sample size of 400 participants. Ethical approval
for this study was sought and received from Leeds East
Research Ethics Committee on 19 March 2015 (REC Ref:
15/YH/0051). The schedule of enrolment, interventions
and assessments is shown in Fig. 1. Additional file 1:
Table S1 presents the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) Checklist.
Identification and recruitment
Potential participants will be recruited using five methods:
1. GP database screening
Participating GP practices will search their patient
databases and SMI register to identify potential
participants. Suggested Read codes will be provided
to assist with database searches. Participant
information packs will be sent to identified patients
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by the GP practice to invite them to take part in the
study. Those interested in taking part will be asked
to complete and return a Consent to be Contacted
Form to the SCIMITAR+ researchers, who will then
approach the potential participant to confirm
eligibility and obtain consent.
2. Direct GP referral or primary care referral following
annual health check
People with SMI consult with their GPs frequently,
largely in connection with physical rather than
mental health problems. Current guidelines
encourage GPs to offer opportunistic advice and
information about smoking-cessation services to all
patients who smoke whenever they consult in
primary care. Such opportunistic advice provides a
chance for GPs to introduce the SCIMITAR+ trial
to potential participants. Those interested in taking
part will be asked to complete a Consent to be
Contacted Form which the GP will return to the
SCIMITAR+ researchers, who will then approach
the potential participant to confirm eligibility and
obtain consent.
3. Direct referral via Community Mental Health Teams
(CMHTs) and psychiatrists
SCIMITAR+ researchers will work with care
coordinators and consultant psychiatrists to screen
their entire caseloads for potential participants who
match the inclusion criteria. Those identified as
potentially suitable for the SCIMITAR+ trial will be
given a copy of the participant information pack by
their care coordinator or psychiatrist. The
participant information pack will contain a Consent
to be Contacted Form which potential participants
can return to the SCIMITAR+ research team
Members of the CMHT will also be invited to
directly refer potential participants to the research
team, following a similar pathway to GP referrals.
Posters and flyers advertising the study will be
displayed in centres recruiting to the study, on
Facebook and Twitter accounts, and in third-sector
community organisations. Interested service users
can contact the mental health professional named
on the flyer, or a member of their care team, to
request participant information packs.
4. Recruitment from service user groups
Service user groups will be provided with
information about the study along with copies of a
SCIMITAR flyer. Interested service users can
contact the mental health professional named on the
flyer or their care coordinator. Alternatively, the staff
member at the service user group can contact the
service user’s care coordinator on their behalf.
5. Recruitment via the Lifestyle Health and
Wellbeing Survey
The Lifestyle Health and Wellbeing Survey is a
questionnaire-based study, coordinated by the
University of York (REC ref: 15/WM/0444)
involving adults aged 18 years and over with SMI
recruiting from direct referrals of primary and
secondary care teams. Participants in the Lifestyle
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure – schedule of enrolment, intervention and assessments
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Health and Wellbeing Survey complete a series of
questions about their health and wellbeing including
questions about their smoking status. Survey res-
pondents who smoke and are potentially interested
in cutting down or quitting smoking, and have
consented to being contacted by the research
team, will be invited to take part in SCIMITAR+.
Screening for eligibility
Once a potential participant has given consent to be con-
tacted (either verbally to the recruiting clinician or in writ-
ing), a SCIMITAR+ researcher will approach them either
by telephone, face to face or by e-mail depending on the
participant’s preference. After briefly explaining the trial
the researcher will check the participant’s eligibility and
then, if eligible, will arrange a face-to-face appointment at
a mutually convenient time and venue.
At the face-to-face appointment the potential par-
ticipant will be provided with the opportunity to ask any
additional questions about the study and provide written
informed consent. Once written consent has been
obtained the participant will complete the baseline
questionnaire with the researcher.
Inclusion and exclusion criteria
Inclusion:
 Aged 18 years or over.
 A documented diagnosis of schizophrenia or
delusional/psychotic illness (International
Classification of Diseases, version 10 (ICD-10) F20.X
and F22.X or Diagnostic and Statistical Manual of
Mental Disorders (DSM)-equivalent) or bipolar
disorder (ICD-10 F31.X or DSM-equivalent).
 Current smoker, smoking at least five tobacco
cigarettes per day.
 Express a desire to cut down or quit smoking.
Exclusion:
 Pregnant or breast-feeding women.
 Known comorbid drug or alcohol dependency
(as recorded in GP or psychiatric records).
 Currently receiving advice from a stop smoking
advisor.
 Non-English speaking.
 Lack of capacity to consent.
Randomisation and blinding
Eligible, consenting participants will be randomised 1:1
to either a bespoke smoking-cessation service or usual
care. The researcher will contact a secure telephone ran-
domisation service run by the York Trials Unit. Simple
randomisation will be used, following a computer-
generated random number sequence. The researcher will
immediately inform the participant of their allocation
and what will happen next. A letter will be sent to the
GP and mental health specialist for filing in the par-
ticipant’s records and to advise them on subsequent
smoking-cessation management.
Neither the nature of the interventions in this study
nor the study design allows for the masking of the thera-
pists or the participants. However, statistical analysis will
be conducted blind to treatment allocation.
Interventions
Smoking-cessation intervention
This is a complex intervention involving a bespoke
smoking-cessation service provided by a mental health
professional trained in smoking-cessation interventions.
The mental health smoking-cessation practitioner (MH-
SCP) will work in conjunction with the participant and
the participant’s general practitioner (GP) or mental
health specialist to provide a smoking-cessation service
individually tailored to the participant’s needs. The par-
ticipant will be offered between eight and 12 sessions
with the MH-SCP. The intervention will be delivered
according to the National Centre for Smoking Cessation
and Training’s guidelines with the following specific
adaptations for people with SMI: in line with National
Institute of Health and Care Excellence (NICE) guide-
lines for smoking cessation [17]:
1. The possibility of providing several sessions prior to
setting a ‘quit date’.
2. Recognising the purpose of smoking in the
context of their mental illness, such as the use of
smoking to relieve side effects from antipsychotic
medication (and how this will be managed during
a cessation attempt).
3. The need to involve other members of the
multidisciplinary team in planning a successful quit
attempt for those with complex care needs and
multiagency programmes of care.
4. A greater need for home visits, rather than planned
visits in GP surgeries (for some clients with mental
illness, the home environment is the optimum place
to work).
5. Providing additional face-to-face support following
an unsuccessful quit attempt or relapse.
6. Informing the GP and psychiatrist of a
successful quit attempt so that they can
review antipsychotic medication doses if the
participant’s metabolism changes.
Control group
This will be a ‘usual care’ control group whereby the par-
ticipants will be signposted towards usual care for their
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area. Usual care varies according to where the partici-
pant is geographically located and is dependent on local
commissioning arrangements. One example consists of
participants attending their local GP service on a fort-
nightly basis to have their expired carbon monoxide
(CO) measured by the in-house smoking-cessation prac-
titioner and to collect their ongoing nicotine rep-
lacement therapy (NRT) prescription. In other areas
participants are referred to a local smoke-free NHS
service for the same fortnightly meetings but with an
additional initial assessment of nicotine dependence and
motivation to quit as well as requiring participants to set
a ‘quit day’ when they will stop smoking. In some in-
stances, smoke-free services offer weekly individual or
group meetings for motivational and behavioural sup-
port at a local centre or pharmacy. In another example
participants may visit their GP who provides an NRT
prescription and refers patients to a local council-funded
project for individual behavioural support.
Outcome measures
Data will be collected from participants at baseline and
at 6 and 12 months post randomisation. Baseline and
follow-up assessments will take place during face-to-face
meetings with the participant in order to measure height
and weight to calculate the Body Mass Index (BMI), and
to take CO readings. As face-to-face follow-up is pre-
ferred every effort will be made to collect, as a mini-
mum, a reduced set of data by this method. Where it is
not possible to meet with the participant for face-to-face
follow-up data collection, the participant will be offered
the option of completing the questionnaires by tele-
phone or have the questionnaires sent to them by post
for them to complete and return. If it is not possible to
make contact with the participant for follow-up, a family
member or friend named by the participant at their
baseline interview as a person who could be contacted,
will be asked to verify the participant’s smoking status.
The primary outcome measure will be cessation of
smoking at 12 months assessed according to the Russell
standard. Smoking cessation will be defined as having an
expired-air CO measurement of less than 10 ppm and
self-reporting as a quitter (responding ‘not even a puff ’
to the question ‘Have you smoked in the last week?’).
Secondary outcomes at 6 and 12 months post random-
isation will include measures of smoking status, general
mental health functioning, BMI, health-related quality of
life, health service use, and adherence with smoking-
cessation advice from MH-SCP (Table 1). The flow of
participants through the trial is shown in Fig. 2.
Withdrawal
A study participant may be withdrawn from the trial by
their general practitioner (GP), mental health specialist,
smoking-cessation practitioner or may choose to do so
themselves. Reasons for withdrawal may include preg-
nancy, admission to hospital for reasons unrelated to the
trial, inability to attend treatment or assessment ses-
sions. Relapse to resuming smoking is not seen as reason
to withdraw since participants can resume treatment
and make several attempts to quit smoking. Participants
will be able to (1) withdraw from treatment only (partici-
pants still followed up at 6 and 12 months) or (2) with-
draw fully from the study including from treatment and
follow-up. Withdrawal from the study does not affect
the patients’ treatment or access to NHS services. Any
data collected from the participant prior to withdrawal
will still be included in the final analysis of the data. In
the case of missing primary outcome data due to with-
drawal it will be assumed that the participant is still
Table 1 Outcome measure and collection time point
Assessment Time point (months
post randomisation)
Baseline 6 12
Eligibility and consent
Eligibility X
Consent X
Background and follow-up
Personal details, general health X
Body Mass Index X X X
Mental health details
Mental health history X
Current mental health status X X X
Current medications X X X
Referrals to mental health services X X
Admissions to hospital related to mental health X X
Smoking details
Smoking history X
Current smoking status X X X
Use of electronic cigarettes X X X
Use of smoking-cessation services X X X
CO measurement X X X
Adverse event reporting Ongoing collection
Questionnaires
Fagerström Test for Nicotine Dependence
(FTND) [17]
X X X
Motivation to Quit questionnaire (MTQ) X X X
Patient Health Questionnaire (PHQ-9) X X X
Generalised Anxiety Disorder Assessment (GAD-7) X X X
Health-related quality of life (SF-12) X X X
Health-state utility (EuroQol – EQ-5D-5L) X X X
Health Economics/Service Utilisation
Questionnaire
X X X
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smoking. For further details about how missing data will
be handled please see the ‘Data analysis’ section below.
Sample size
The SCIMITAR+ trial has been powered to detect a rela-
tive increase in quitting of 1.7 (baseline quit rate 20%,
intervention quit rate 34%) using a two-sided significance
level of 5% at 80% power. This would require a sample
size of 314 participants using equal (1:1) randomisation.
Allowing for a 20% loss to follow-up would give a total
sample size of at least 393. We therefore propose to re-
cruit 400 participants in total to ensure sufficient power.
Data analysis
All analyses will be conducted on an intention-to-treat
basis, including all randomised patients in the groups to
which they were allocated where data are available.
Analyses will be conducted in STATA v13 or later
(StataCorp, College Station, TX, USA). Statistical tests
will be two-sided using 5% significance.
The flow of participants through the trial will be
described in a Consolidated Standards of Reporting
Trials (CONSORT) diagram. The number of withdrawals
will be summarised by type, treatment group and time,
with reasons where provided.
All participant baseline data will be summarised de-
scriptively by treatment group both as randomised and
as analysed in the primary analysis. No formal statistical
comparisons will be undertaken.
The primary outcome of CO-verified smoking cessa-
tion at 12 months will be analysed via a mixed-effects
logistic regression model to compare bespoke smoking-
cessation services with usual care. The model will be
adjusted for baseline smoking severity (self-reported
Fig. 2 Participant flow through the trial
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number of cigarettes smoked) and treatment group, with
centre as a random effect. The odds ratio, corresponding
two-sided 95% confidence interval and p value for the
treatment effect will be presented.
In a sensitivity analysis, we will substitute CO-verified
results with self-reported cessation results where CO
results are missing. Two further sensitivity analyses will be
conducted treating participants who still have missing
primary outcome data in the following two ways: (1)
patients with missing data will be assumed to still be smok-
ing and (2) multiple imputation techniques will be used.
All data collected at 6 and 12 months will be sum-
marised descriptively by treatment group, including an
investigation of the level of missing data.
The primary analysis will be repeated using, as the
outcome: (1) CO-verified smoking cessation at 6 months,
(2) self-reported smoking cessation at 6 months, and (3)
self-reported smoking cessation at 12 months.
The number of cigarettes smoked per day will be com-
pared between the two groups using a Poisson regres-
sion model, adjusting for the same covariates as the
primary analysis. If the variance of the data is larger than
the mean, this may give an indication that the data are
over-dispersed. In this case, a negative binomial model
will be run. If the data are zero-inflated, then a zero-
inflated Poisson or negative binomial model will be used.
Incidence rate ratios and their associated 95% confi-
dence intervals and p values will be provided.
The FTND, the Motivation to Quit questionnaire
(MTQ), the Patient Health Questionnaire-9 (PHQ-9),
the Generalised Anxiety Questionnaire-7 (GAD-7), the
12-item Short Form Health Survey (SF-12) physical
component, SF-12 mental component scores, and BMI
will all be analysed in the same way. Scores at 6 and
12 months will be compared between treatment groups
using a repeated-measures covariance pattern mixed
model including as fixed effects: baseline score, treat-
ment group, time and a treatment group × time inter-
action term. Different covariance structures for the
repeated measurements, that are available as part of
STATA v13 (or later), will be explored and the most
appropriate pattern will be used for the final model. Diag-
nostics including Akaike’s information criterion will be
compared for each model (smaller values are preferred).
Model assumptions will be checked. Estimates of the dif-
ference between treatment groups will be derived at all
time points with 95% confidence intervals and p values.
Self-reported number of attempts to quit, periods of
cessation, electronic cigarette use, and adverse events
will be summarised descriptively by treatment group.
A complier average causal effect (CACE) analysis for
the primary outcome will be conducted to obtain un-
biased estimates of the intervention effectiveness in the
presence of full compliance. We will define compliance
with the intervention for those allocated to bespoke
smoking cessation service (BSC) as the number of ses-
sions attended.
Economic analysis
Economic evaluation will be carried out in the form of
an incremental cost-effectiveness analysis over the 12-
month trial period, from a NHS and personal and social
service perspective [18]. Intervention costs will be re-
corded by the research team and include delivery costs
within the trial, supervision costs and appropriate capital
costs. Resource use in physical units will be collected
using an adapted Health Economic/Service Utilisation
Questionnaire and case notes. Resource units will be
valued by multiplying quantities by the corresponding
market prices or national average unit costs.
Health-related quality of life will be measured using
the EuroQol 5 dimensions, 5 levels (EQ-5D-5 L) ques-
tionnaire [19]. Health utilities are converted into quality-
adjusted life years (QALYs), by calculating the area
under curve [20]. An incremental cost-effectiveness ratio
(ICER) will be calculated by combining difference in
costs between groups and difference in QALYs between
groups and compared with the national willingness-to-
pay threshold to determine cost-effectiveness.
Discussion
People with SMI experience significant health inequalities
and one of the most important modifiable risk factors for
reduced life expectancy is smoking. It is, therefore, im-
portant to develop evidence-based interventions to help
people with SMI to quit smoking. The SCIMITAR+ trial
is the largest trial to our knowledge to investigate the
clinical effectiveness and cost-effectiveness of a bespoke
smoking-cessation service for people with severe mental
ill health.
Study status
Recruitment to the SCIMITAR+ trial began in October
2015 and results are expected in 2018.
Additional file
Additional file 1: Table S1. SPIRIT Checklist. (DOC 123 kb)
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